Mean (SD) change in FEV1 (l) over 26 weeks | 0.001 (0.14) | 0.06 (0.26) | −0.002 (0.14) | 0.4 |
Change in β2 agonist use (puffs/day) at 26 weeks | 0 (−2 to 0) | −2 (−4 to 0) | 0 (−2 to 0) | 0.005 |
Number of exacerbations | 1 (0–2) | 1 (0–1.75) | 1 (0–2) | 0.7 |
Days taking increased dose of inhaled steroid | 0 (0–16) | 0 (0–11) | 1 (0–7) | 0.9 |
Median (range) number of prednisolone courses per subject | 0 (0–l) | 0 (0–2) | 0 (0–1) | 0.4 |
Change in overall asthma quality of life score† | 0.61 (−0.11 to 0.95) | 1.03 (0.19 to 1.69) | 0.57 (0.07 to 1.10) | 0.2 |
Reduction in inhaled steroids (%) in steroid reduction phase | 0 (0–50) | 41.5 (0–100) | 25 (0–62.5) | 0.7 |